<HashMap><database>biostudies-literature</database><scores/><additional><submitter>Zhu L</submitter><funding>Key Research and Development Program of Shaanxi Province</funding><funding>Health Research and Innovation Capacity Enhancement Program of Shaanxi Province</funding><funding>National Natural Science Foundation of China</funding><pagination>19</pagination><full_dataset_link>https://www.ebi.ac.uk/biostudies/studies/S-EPMC12748425</full_dataset_link><repository>biostudies-literature</repository><omics_type>Unknown</omics_type><volume>83(1)</volume><pubmed_abstract>Vascular calcification is a pathological process commonly associated with cardiovascular diseases, diabetes, and renal insufficiency, driven by inflammation, oxidative stress, and endoplasmic reticulum stress. IL-38, a member of the IL-1 cytokine family, has shown anti-inflammatory, antioxidant, and anti-fibrotic effects in cardiovascular contexts. However, its role in vascular calcification remains unknown. This study demonstrated significantly reduced IL-38 expression in human calcified coronary tissues, patient plasma, and experimental models. IL-38 knockout mice exhibited aggravated vascular calcification, while treatment with recombinant IL-38 protein markedly suppressed calcification. RNA sequencing revealed that IL-38 alleviates oxidative stress by upregulating glutathione peroxidas</pubmed_abstract><journal>Cellular and molecular life sciences : CMLS</journal><pubmed_title>IL-38 attenuates vascular calcification by upregulating GPX3-mediated antioxidant defense via the PPAR-γ/NRF2 axis.</pubmed_title><pmcid>PMC12748425</pmcid><funding_grant_id>2023-ZDLSF-39</funding_grant_id><funding_grant_id>82170336</funding_grant_id><funding_grant_id>2024TD-05</funding_grant_id><pubmed_authors>Shang B</pubmed_authors><pubmed_authors>Jing L</pubmed_authors><pubmed_authors>Cui J</pubmed_authors><pubmed_authors>Li P</pubmed_authors><pubmed_authors>Liu R</pubmed_authors><pubmed_authors>Sun Y</pubmed_authors><pubmed_authors>Yi W</pubmed_authors><pubmed_authors>Xin J</pubmed_authors><pubmed_authors>Wang Q</pubmed_authors><pubmed_authors>Zhu L</pubmed_authors><pubmed_authors>Cui Y</pubmed_authors><pubmed_authors>Chen W</pubmed_authors><pubmed_authors>Tang W</pubmed_authors><pubmed_authors>Zhang B</pubmed_authors><pubmed_authors>Zhou H</pubmed_authors><pubmed_authors>Song Y</pubmed_authors></additional><is_claimable>false</is_claimable><name>IL-38 attenuates vascular calcification by upregulating GPX3-mediated antioxidant defense via the PPAR-γ/NRF2 axis.</name><description>Vascular calcification is a pathological process commonly associated with cardiovascular diseases, diabetes, and renal insufficiency, driven by inflammation, oxidative stress, and endoplasmic reticulum stress. IL-38, a member of the IL-1 cytokine family, has shown anti-inflammatory, antioxidant, and anti-fibrotic effects in cardiovascular contexts. However, its role in vascular calcification remains unknown. This study demonstrated significantly reduced IL-38 expression in human calcified coronary tissues, patient plasma, and experimental models. IL-38 knockout mice exhibited aggravated vascular calcification, while treatment with recombinant IL-38 protein markedly suppressed calcification. RNA sequencing revealed that IL-38 alleviates oxidative stress by upregulating glutathione peroxidas</description><dates><release>2025-01-01T00:00:00Z</release><publication>2025 Nov</publication><modification>2026-06-06T09:31:40.171Z</modification><creation>2026-05-28T03:12:01.922Z</creation></dates><accession>S-EPMC12748425</accession><cross_references><pubmed>41307654</pubmed><doi>10.1007/s00018-025-05990-5</doi></cross_references></HashMap>